Survey

Help us improve Glivec.com. Please take our short survey.

TAKE SURVEY
Printer-Friendly Version | Email This Page

References

1. Fletcher CDM, Berman JJ, Gorstein F, et al. Diagnosis of gastrointestinal stromal tumours: a consensus approach. Hum Pathol. 2002;33:459-465.

2. Joensuu H. Current perspectives on the epidemiology of gastrointestinal stromal tumours. Eur J Cancer. 2006;4(suppl 1):4-9.

3. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol. 2004;11:464-475.

4. Demetri G, Benjamin R, Blanke CD, et al. NCCN Task Force Report: optimal management of patients with gastrointestinal stromal tumour (GIST)--expansion and update of NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw. 2004;2(suppl 1):S1-S26.

5. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumours: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-58.

6. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumours. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of European Society for Medical Oncology. Ann Oncol. 2005;16:566-578.

7. Bucher P, Villiger P, Egger JF, Buhler LH, Morel P. Management of gastrointestinal stromal tumours: from diagnosis to treatment. Swiss Med Wkly. 2004;134:145-153.

8. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours,Br J Surg. 2003;90:1178-1186.

9. Miettinen M, Lasota J. Gastrointestinal stromal tumours--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1-12.

10. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumours: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer. 2005;103:821-829

11. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005;41:2868-2872.

12. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumour (GIPACT): gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259-1269.

13. Torihashi S, Horisawa M, Watanabe Y. c-Kit immunoreactive interstitial cells in the human gastrointestinal tract. J Auton Nerv Syst. 1999;75:38-50.

14. Thomsen L, Robinson TL, Lee JC, et al. Interstitial cells of Cajal generate a rhythmic pacemaker current. Nat Med. 1998;4:848-851.

15. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumours: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28:889-894.

16. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumours. Science. 2003;299:708-710.

17. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer. 2002;38(suppl 5):S3-S10.

18. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumours. J Clin Oncol. 2004;22:3813-3825.

19. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumours: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484-495.

20. Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res. 2001;80:1-38.

21. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours. Science. 1998;279:577-580.

22. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumours. Gastroenterology. 2003;125:660-667.

23. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation.Appl Immunohistochem Mol Morphol. 2005;13:205-220.

24. Kindblom LG. Gastrointestinal stromal tumours: diagnosis, epidemiology, prognosis. Available at: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Virtual +Meeting?&vmview=vm_session_presentations_view&confID=23&sessionID=292. Accessed July 13, 2007.

25. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002;3:655-664.

26. Ghanem N, Altehoefer C, Furtwangler A, et al. Computed tomography in gastrointestinal stromal tumours. Eur Radiol. 2003;13:1669-1678.

27. Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology. 2005;47:41-47.

28. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumours (GISTs): a review. Eur J Cancer. 2002;38(suppl 5):S39-S51.

29. Reichardt P. Optimising therapy for GIST patients. Eur J Cancer. 2006;4(suppl 1):19-26.

30. Miettinen M, El-Rifai W, L HLS, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumours: a review. Hum Pathol. 2002;33:478-483.

31. Demetri G, von Mehren M, Joensuu H, et al. Long-term clinical outcomes of imatinib treatment in patients with advanced gastrointestinal stromal tumours. J Clin Oncol. Manuscript submitted.

32. Blanke CD, Demetri G, von Mehren M, et al. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumour (GIST) patients (pts) treated with imatinib mesylate [abstract]. J Clin Oncol. 2006;24:526s. Abstract 9528.

33. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumours: before and after STI-571. Hum Pathol. 2002;33:466-477.

34. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 2002;1:31-36.

35. Glivec Summary of Product Characteristics [SMPC]. Basel, Switzerland: Novartis Pharma AG; 2006.

36. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukaemia. Blood. 2000;96:3343-3356.

37. D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumours. Cancer Control. 2005;12:44-56.

38. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172-187.

39. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.

40. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104.

41. Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005;105:3127-3132.

42. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001;97:2440-2448.

43. Blanke CD, Joensuu H, Demetri GD, et al. Outcome of advanced gastrointestinal stromal tumour (GIST) patients treated with imatinib mesylate: Four-year follow-up of a phase II randomized trial [abstract]. Presented at: 2006 ASCO Gastrointestinal Cancers Symposium; January 26-28, 2006; San Francisco, Calif. Abstract 7, 2006.

44. Blanke C, Joensuu H, Demetri G, et al. Long-term follow up of advanced gastrointestinal stromal tumour (GIST) patients treated with imatinib mesylate [abstract]. Presented at: 2004 ASCO Gastrointestinal Cancers Symposium; January 23, 2004; San Francisco, Calif., 2004.